SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
These are morphologically polymorphic lesions composed of immunoblasts, plasma cells and small and intermediate sized lymphoid cells that efface the architecture of lymph nodes or form destructive extranodal masses. This is the most common PTLD in children and follows primary EBV infection.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see codes 9970/1 or 9975/1.)
PTLD is a lymphoid proliferation arising in a recipient of a solid organ transplant, allogenic bone marrow transplantation, or an umbilical cord blood transfusion. The patient must have a history of a solid organ transplant or an allogenic bone marrow transplant. The polymorphic PTLD is actually caused by the post-transplant T-cell immunosuppressant drugs. Most cases of polymorphic PTLD occur within a year of transplantation; however, they can occur anytime after the transplant.